Rosa Daniela D, Ismael Gustavo, Lago Lissandra Dal, Awada Ahmad
Medical Oncology Clinic, Jules Bordet Institute, and L Universite Libre de Bruxelles (ULB), Brussels, Belgium.
Cancer Treat Rev. 2008 Feb;34(1):61-80. doi: 10.1016/j.ctrv.2007.07.019. Epub 2007 Sep 10.
Over the past decade, molecular-targeted therapies have been added to cytotoxic and anti-endocrine drugs in the treatment of cancer, with the aim to target the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of the drug target is the starting point for the route of development of active, safe and effective drugs. Main molecular targets used to the development of anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins and tumour microenvironment components (especially antiangiogenic agents). Here, we review the development of the main molecular targeted non-cytotoxic agents studied in cancer, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecular-targeted therapies.
在过去十年中，分子靶向疗法已被添加到细胞毒性和抗内分泌药物中用于癌症治疗，目的是针对致癌过程及维持癌症表型的分子途径。其中一些药物取得的成功表明，药物靶点的识别和验证是开发活性、安全和有效药物途径的起点。用于抗癌药物开发的主要分子靶点是细胞表面受体、信号转导途径、基因转录靶点、泛素 - 蛋白酶体/热休克蛋白以及肿瘤微环境成分（尤其是抗血管生成剂）。在此，我们综述了在癌症研究中主要分子靶向非细胞毒性药物的开发情况，强调从这些新药开发中获得的经验教训，并为分子靶向疗法的临床开发提出新的前景。
